497 results on '"Berk, David R"'
Search Results
2. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
3. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies
4. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
5. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
6. The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
7. Osseous metaplasia late in the course of nephrogenic systemic fibrosis
8. Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
9. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis
10. Epidermodysplasia verruciform-like Lesions in an HIV patient
11. Burkitt lymphoma with cutaneous involvement
12. Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial
13. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies
14. Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)
15. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
16. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis
17. 33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area
18. 33467 Long-term safety and efficacy of roflumilast cream 0.3% in patients with chronic plaque psoriasis: Interim results from a 24-week, phase 3 open-label study
19. 33468 Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2)
20. 53894 Roflumilast foam 0.3% once daily in patients with seborrheic dermatitis: Improvement in patient reported outcomes and pruritus from a phase 3 trial (STRATUM)
21. 53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis
22. 53817 Patient-reported outcomes with roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial
23. 641 - Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis.
24. 638 - Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial.
25. 637 - ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis.
26. 28588 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a randomized, double-blind, vehicle-controlled phase 2 study
27. 28043 Roflumilast cream significantly improves chronic plaque psoriasis in patients with steroid-sensitive area involvement
28. 27874 Correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes in patients with chronic plaque psoriasis
29. 27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor
30. Cutis laxa: A review
31. Milia: A review and classification
32. Skin findings in Williams syndrome
33. Oral Glycopyrrolate for Refractory Pediatric and Adolescent Hyperhidrosis
34. Dichotomous Long-Term Response to Isotretinoin in Two Patients with Fordyce Spots
35. Trichodysplasia spinulosa in an adolescent with cystic fibrosis and lung transplantation
36. Focal Preauricular Dermal Dysplasia in a Newborn
37. Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities
38. Disease progression among HIV-infected children who receive perinatal zidovudine prophylaxis
39. Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study
40. Dermatologic Disorders Associated With Chronic Hepatitis C: Effect of Interferon Therapy
41. Circumscribed acral hypokeratosis
42. Associations of changes in exercise level with subsequent disability among seniors: a 16-year longitudinal study
43. 15309 ARQ-151, roflumilast cream, improved psoriasis in phase 2a study
44. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort
45. Temporal Trends in Mucocutaneous Findings Among Human Immunodeficiency Virus 1-Infected Children in a Population-Based Cohort
46. Scleral Hemangioma: Case Report and Response to Propranolol
47. Diagnosing Epidermolysis Bullosa Type and Subtype in Infancy Using Immunofluorescence Microscopy: The Stanford Experience
48. ON TOPICAL TIMOLOL GEL-FORMING SOLUTION FOR INFANTILE HEMANGIOMAS
49. Topical Cidofovir for Refractory Verrucae in Children
50. Sildenafil for Severe Lymphatic Malformations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.